Noile-Immune Biotech Inc. (TYO:4893)

Market Cap	6.50B -10.7%
Revenue (ttm)	5.00M -28.6%
Net Income	-793.00M
EPS	-18.31
Shares Out	43.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,700
Average Volume	376,150
Open	153.00
Previous Close	151.00
Day's Range	148.00 - 153.00
52-Week Range	126.00 - 217.00
Beta	-0.01
RSI	47.51
Earnings Date	May 14, 2026

About Noile-Immune Biotech

Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company’s product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 23
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4893

Financial Performance

In 2025, Noile-Immune Biotech's revenue was 5.00 million, a decrease of -28.57% compared to the previous year's 7.00 million. Losses were -793.00 million, -17.74% less than in 2024.